ijms-logo

Journal Browser

Journal Browser

Molecular and Cellular Targets on Anticancer Research and Perspectives

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 1910

Special Issue Editor


E-Mail Website
Guest Editor
President Scientific Council, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: nutrition; gastroenterology; inflammatory bowel disease; hepatology; cancer epidemiology; experimental and translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Anticancer research remains the top priority in biomedical research.

Without doubt, artificial intelligence (AI) and new technologies are currently our best tools for scientific research, making the development of new, innovative strategies more feasible than ever before.

The National Cancer Institute defines oncologic precision medicine as the “use of specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis”. Specific information about a person’s tumor includes the identification of specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer.

All medical specialties and scientists must work together to reach our goal: to transform cancer from a lethal disease into a chronic disease. AI, personalized medicine, and new techniques (in both oncology and surgery) represent the driving force behind current basic and clinical research.

For this Special Issue, we invite the submission of original research and review papers on targeted cancer therapies, which can cover any malignancy.

Dr. Apostolos E. Papalois
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer
  • molecular targets
  • targeted cancer therapies
  • malignancy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2715 KB  
Article
Effects of Disulfiram and Copper in Combination with Temozolomide on Survival, Tumor Size and Autophagy Markers in an F98 Rat Glioma Model
by Petros N. Karamanakos, Maria Fouka, Diamanto Aretha, Eleftheria S. Panteli, Ioannis Panopoulos, Dimitris Kletsas, Anna Goussia, Alexandra Papoudou-Bai, Argyro Zacharioudaki, Dimitrios T. Trafalis, Kyriakos Orfanakos, Marios Marselos, Maria Xilouri and Apostolos Papalois
Int. J. Mol. Sci. 2026, 27(4), 1966; https://doi.org/10.3390/ijms27041966 - 18 Feb 2026
Viewed by 1389
Abstract
Glioblastoma (GBM) is the most common and most aggressive malignant primary brain tumor in adults with a median survival of 15 months. One of the main factors responsible for the poor prognosis of GBM is resistance to treatment with temozolomide (TMZ), which has [...] Read more.
Glioblastoma (GBM) is the most common and most aggressive malignant primary brain tumor in adults with a median survival of 15 months. One of the main factors responsible for the poor prognosis of GBM is resistance to treatment with temozolomide (TMZ), which has been attributed—among other factors—to autophagy. Preclinical studies have shown that the combination of disulfiram (DSF) with copper (Cu) possesses anti-GBM activity, through various mechanisms, including re-sensitization to TMZ. Herein, we tested for the first time the effects of DSF and Cu in combination with TMZ on the survival of Fischer rats bearing F98 glioma, a model characterized by inherent resistance to TMZ. Tumor size evaluation by Magnetic Resonance Imaging as well as immunofluorescence analysis of two autophagy markers, namely microtubule-associated protein 1 light chain 3 (LC3) and sequestosome-1 (SQSTM1)/p62 (p62), were also performed. According to our results, TMZ-DSF-Cu significantly increased mean survival and induced both LC3 and p62 autophagy markers. Interestingly, these results could not be achieved in the absence of Cu, neither in the presence of TMZ alone, suggesting the importance of combining DSF with Cu in order to sensitize glioma to TMZ, presumably via implication of autophagy modulation. Full article
Show Figures

Figure 1

Back to TopTop